BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

被引:130
作者
Matros, E
Wang, ZGC
Lodeiro, G
Miron, A
Iglehart, JD
Richardson, AL
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
关键词
basal-like breast cancer; BRCA1; gene expression arrays; methylation;
D O I
10.1007/s10549-004-7603-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BRCA1 is a tumor suppressor gene that functions in DNA repair. Basal-like tumors are a distinctive subtype of breast cancer defined by gene expression profiles. Hereditary BRCA1 breast tumors and basal-like sporadic tumors have a similar phenotype and gene expression signature, suggesting involvement of BRCA1 in the pathogenesis of sporadic basal-like cancer. This study evaluates the role of BRCA1 in sporadic breast tumorigenesis. BRCA1 protein expression and promoter methylation are compared to tumor histopathology and gene expression profiles. We find BRCA1 protein expression correlates with tumor mitotic rate, consistent with normal cell-cycle regulation of the BRCA1 gene. Methylation is found in 21% of tumors and is associated with lower BRCA1 protein, but not with specific pathologic features. Basal-like tumors, defined by hierarchical clustering of gene expression, have infrequent BRCA1 methylation and high levels of BRCA1 protein expression consistent with their high mitotic rate. Tumors with BRCA1 promoter methylation are present in all expression clusters; however, a subgroup of ER-positive high-grade tumors has a significantly greater number of BRCA1 methylated tumors. Absence of BRCA1 promoter methylation and high levels of BRCA1 expression in basal-like sporadic tumors suggest alternate explanations for the phenotypic similarities of these tumors to hereditary BRCA1 tumors.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 50 条
[1]   The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].
Bhattacharyya, A ;
Ear, US ;
Koller, BH ;
Weichselbaum, RR ;
Bishop, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903
[2]   Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer:: correlation with disease characteristics [J].
Catteau, A ;
Harris, WH ;
Xu, CF ;
Solomon, E .
ONCOGENE, 1999, 18 (11) :1957-1965
[3]   A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer [J].
Chapppuis, PO ;
Goffin, J ;
Wong, N ;
Perret, C ;
Ghadirian, P ;
Tonin, PN ;
Foulkes, WD .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (08) :608-610
[4]   ABERRANT SUBCELLULAR-LOCALIZATION OF BRCA1 IN BREAST-CANCER [J].
CHEN, YM ;
CHEN, CF ;
RILEY, DJ ;
ALLRED, DC ;
CHEN, PL ;
VONHOFF, D ;
OSBORNE, CK ;
LEE, WH .
SCIENCE, 1995, 270 (5237) :789-791
[5]  
CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
[6]   Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors [J].
Esteller, M ;
Silva, JM ;
Dominguez, G ;
Bonilla, F ;
Matias-Guiu, X ;
Lerma, E ;
Bussaglia, E ;
Prat, J ;
Harkes, IC ;
Repasky, EA ;
Gabrielson, E ;
Schutte, M ;
Baylin, SB ;
Herman, JG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) :564-569
[7]   DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis [J].
Esteller, M ;
Fraga, MF ;
Guo, MZ ;
Garcia-Foncillas, J ;
Hedenfalk, I ;
Godwin, AK ;
Trojan, J ;
Vaurs-Barrière, C ;
Bignon, YJ ;
Ramus, S ;
Benitez, J ;
Caldes, T ;
Akiyama, Y ;
Yuasa, Y ;
Launonen, V ;
Canal, MJ ;
Rodriguez, R ;
Capella, G ;
Peinado, MA ;
Borg, A ;
Aaltonen, LA ;
Ponder, BA ;
Baylin, SB ;
Herman, JG .
HUMAN MOLECULAR GENETICS, 2001, 10 (26) :3001-3007
[8]   A GENOMIC SEQUENCING PROTOCOL THAT YIELDS A POSITIVE DISPLAY OF 5-METHYLCYTOSINE RESIDUES IN INDIVIDUAL DNA STRANDS [J].
FROMMER, M ;
MCDONALD, LE ;
MILLAR, DS ;
COLLIS, CM ;
WATT, F ;
GRIGG, GW ;
MOLLOY, PL ;
PAUL, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1827-1831
[9]   BRCA1 MUTATIONS IN PRIMARY BREAST AND OVARIAN CARCINOMAS [J].
FUTREAL, PA ;
LIU, QY ;
SHATTUCKEIDENS, D ;
COCHRAN, C ;
HARSHMAN, K ;
TAVTIGIAN, S ;
BENNETT, LM ;
HAUGENSTRANO, A ;
SWENSEN, J ;
MIKI, Y ;
EDDINGTON, K ;
MCCLURE, M ;
FRYE, C ;
WEAVERFELDHAUS, J ;
DING, W ;
GHOLAMI, Z ;
SODERKVIST, P ;
TERRY, L ;
JHANWAR, S ;
BERCHUCK, A ;
IGLEHART, JD ;
MARKS, J ;
BALLINGER, DG ;
BARRETT, JC ;
SKOLNICK, MH ;
KAMB, A ;
WISEMAN, R .
SCIENCE, 1994, 266 (5182) :120-122
[10]   High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families [J].
Ganguly, T ;
Dhulipala, R ;
Godmilow, L ;
Ganguly, A .
HUMAN GENETICS, 1998, 102 (05) :549-556